← Back to Clinical Trials
RecruitingNCT05106036

Preventing Cognitive Decline by Reducing BP Target Trial

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionCognitive Decline
SponsorUniversity of Texas Southwestern Medical Center
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment4,000
SexALL
Min Age70 Years
Max AgeN/A
Start Date2022-07-11
Completion2026-08-31
Interventions
Clinical Support Decision Tool

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who receive care with a combination of clinical decision support (CDS) and team-based care delivered in primary care practices will have better blood pressure control and a lower incidence of mild cognitive impairment and dementia than patients receiving usual medical care. Patients will be recruited from UT Southwestern Medical Center and Parkland Health \& Hospital System.

Eligibility Criteria

Inclusion Criteria: * High BP defined as at least 1 BP readings of SBP \>= 130 or DBP \>=80 during the 24 months prior to enrollment * Clinic visit with primary care provider within the last 24 months * Ability to write and speak English or Spanish * 70 years of age or older * Ability to understand and willingness to provide informed consent * Owns a smartphone Exclusion Criteria: * Blood pressure consistently \<130/80 mmHg * Presence of dementia, Alzheimer's disease, or significant neurological disease * Major and unstable heart disease (e.g., acute heart failure (systolic or diastolic), acute on chronic heart failure (systolic or diastolic), acute coronary syndrome or cardiac arrest, liver or renal transplantation * Under 70 years of age * Inability to write or speak English or Spanish * Chronic kidney disease stage 5 or ESKD * Chemotherapy * Any conditions judged by the medical providers to contraindicate participation due to risk to patient safety or lack of adherence * Expected li

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology